A 52-year-old man with a 10-year history of Major Depressive Disorder presents to the psychiatry clinic after a relapse. He has been on sertraline 100 mg daily for the past 3 years with good response, but stopped the medication 6 weeks ago on his own. He now reports depressed mood, fatigue, insomnia, and poor concentration. His wife notes he has become withdrawn and irritable. On examination, he appears psychomotor retarded and has poor eye contact. He denies suicidal ideation but admits to passive death wishes. Which of the following is the most appropriate next step in management?

Explanation

## Management of Relapsed Major Depressive Disorder **Key Point:** In a patient with a documented positive response to a specific antidepressant, **reinstatement of the same agent at the previously effective dose** is the first-line strategy for relapse management, provided there are no contraindications or intolerance. ### Rationale for Restarting Sertraline 1. **Prior Response:** This patient had a **10-year history of MDD** with a **3-year period of remission on sertraline 100 mg** — clear evidence of efficacy. 2. **Relapse Trigger:** The relapse was iatrogenic (patient-initiated discontinuation), not due to loss of efficacy or intolerance. 3. **Evidence-Based Practice:** Restarting the same SSRI at the previously effective dose has the highest likelihood of re-achieving remission [cite:Kaplan & Sadock 11e Ch 6]. 4. **No Contraindications:** No mention of side effects, medical comorbidities, or drug interactions that would preclude sertraline. ### Suicide Risk Assessment **High-Yield:** Although this patient denies active suicidal ideation, he endorses **passive death wishes** — a significant risk factor. The presence of: - Chronic relapsing MDD - Recent medication discontinuation - Psychomotor retardation and withdrawal - Passive death wishes ...warrants **close monitoring and regular suicide risk assessment** at each visit, especially in the first 2–4 weeks of reinitiation (when antidepressants may increase suicidality in some patients before therapeutic benefit emerges). **Clinical Pearl:** SSRIs can paradoxically increase suicidal ideation in the first 1–2 weeks of treatment or dose escalation, particularly in young adults and those with impulsivity. Weekly follow-up is prudent. ### Why Other Options Are Suboptimal ```mermaid flowchart TD A[Relapsed MDD on prior SSRI]:::outcome --> B{Prior response documented?}:::decision B -->|Yes| C[Reinstate same SSRI at effective dose]:::action B -->|No| D[Switch to different agent or augment]:::action C --> E[Weekly follow-up + suicide risk assessment]:::action E --> F[Monitor for response over 4-6 weeks]:::action F --> G{Remission achieved?}:::decision G -->|Yes| H[Continue long-term maintenance]:::action G -->|No| I[Consider dose escalation or augmentation]:::action ``` | Approach | Why It's Wrong in This Case | |----------|------------------------------| | **Switch to fluoxetine** | Fluoxetine has a longer half-life and slower onset; switching agents without evidence of sertraline failure is irrational. Fluoxetine is not "more efficacious" — all SSRIs have similar efficacy (~60–70% response rate). | | **ECT as first-line** | ECT is reserved for treatment-resistant depression (failure of ≥2 adequate antidepressant trials), psychotic depression, catatonia, or high acute suicide risk. This patient has not yet been re-trialed on his effective agent. | | **Benzodiazepine monotherapy** | Benzodiazepines are **not antidepressants** and should never be used as monotherapy for MDD. They may be used adjunctively for anxiety/insomnia in the short term (2–4 weeks), but prolonged use risks dependence and does not treat the underlying depression. | **Mnemonic: RAMP** — Relapse management algorithm: - **R**einstate prior effective agent - **A**ssess suicide risk regularly - **M**onitor for response (4–6 weeks) - **P**lan long-term maintenance therapy